Pierre d’Epenoux, ImCheck Therapeutics CEO
A biotech upstart just scored $103M from Pfizer et al to fuel its pursuit of a new (to you) I/O pathway
It isn’t likely you’ve heard a lot about ImCheck Therapeutics.
Its main base in Marseille is close to the science it’s pursuing, far from the …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
